Therapy of trachoma and paratrachoma.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Y F Maichuk.
Explore the source record for details and available documents.
A study was performed on 321 patients with paratrachoma: acute follicular conjunctivitis-189, subacute-132. The first group of patients (108) received 1% Tetracycline ointment 4 to 5 times daily, the second group (103 patients)-1% Tetracycline ointment + 0.1% Dexamethasone eye drops, the third group (110 patients)-Eubetal ointment (tetracycline 0.5%, betamethasone 0.1%, chloramphenicol 1%, colistin). Therapeutic efficacy was higher in groups were antibiotics combined with corticosteroids. Cured in 4 weeks in group I-46.3%, in group II-72.8%, in group III-71.8%, cured in 6 weeks-75.9%, 88.3% and 86.4% respectively.
Proteolytic enzyme inhibitors are capable of preventing decomposition of the collagen structures of the corneal stroma, and also have a regulating influence on various aspects of the inflammatory process. The content of proteolytic enzymes (alpha 1-antitrypsin and alpha 2-macroglobulin) was studied in the tears and the blood serum of patients with herpes viral keratitis, as well as in the blood serum of rabbits with experimentally-induced ophthalmoherpes. Herpetic keratitis was attended by significant changes in the content of proteolysis inhibitors, as well as in the peripheral blood neutral proteases activity, this presumably serving as a nonspecific blood protective reaction to the inflammation. In the tears of patients suffering from herpetic keratitis the inhibitors are expended for binding activated proteases in the cornea. Local application to rabbits of protein preparations with an inhibitory effect (contrykal, gordox) at the acute period of the experimentally-induced ophthalmoherpes produced a marked antiphlogistic effect.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.